Introduction
============

Chronic pain represents an emerging public health issue of massive proportions, particularly in view of aging populations in industrialized nations. Associated facts and figures are daunting: In Europe, chronic musculoskeletal pain of a disabling nature affects over one in four elderly people ([@b49]), while figures from Australia note that older half of older people suffer persistent pain, and up to 80% in nursing home populations ([@b54]). Responses to an ABC News poll in the USA indicated that 19% of adults (38 million) have chronic pain, and 6% (or 12 million) have utilized cannabis in attempts to treat it ([@b1]).

Particular difficulties face the clinician managing intractable patients afflicted with cancer-associated pain, neuropathic pain, and central pain states (eg, pain associated with multiple sclerosis) that are often inadequately treated with available opiates, antidepressants and anticonvulsant drugs. Physicians are seeking new approaches to treatment of these conditions but many remain concerned about increasing governmental scrutiny of their prescribing practices ([@b44]), prescription drug abuse or diversion. The entry of cannabinoid medicines to the pharmacopoeia offers a novel approach to the issue of chronic pain management, offering new hope to many, but also stoking the flames of controversy among politicians and the public alike.

This article will attempt to present information concerning cannabinoid mechanisms of analgesia, review randomized clinical trials (RCTs) of available and emerging cannabinoid agents, and address the many thorny issues that have arisen with clinical usage of herbal cannabis itself ("medical marijuana"). An effort will be made to place the issues in context and suggest rational approaches that may mitigate concerns and indicate how standardized pharmaceutical cannabinoids may offer a welcome addition to the pharmacotherapeutic armamentarium in chronic pain treatment.

Cannabinoids and analgesic mechanisms
=====================================

Cannabinoids are divided into three groups. The first are naturally occurring 21-carbon terpenophenolic compounds found to date solely in plants of the *Cannabis* genus, currently termed phytocannabinoids ([@b109]). The best known analgesic of these is Δ^9^-tetrahydrocannabinol (henceforth, THC)([Figure 1](#fig1){ref-type="fig"}), first isolated and synthesized in 1964 ([@b50]). In plant preparations and whole extracts, its activity is complemented by other "minor" phytocannabinoids such as cannabidiol (CBD) ([Figure 1](#fig1){ref-type="fig"}), cannabis terpenoids and flavonoids, as will be discussed subsequently. Figure 1Molecular structures of four cannabinoids employed in pain treatment.

Long before mechanisms of cannabinoid analgesia were understood, structure activity relationships were investigated and a number of synthetic cannabinoids have been developed and utilized in clinical trials, notably nabilone (Cesamet^®^, Valeant Pharmaceuticals), and ajulemic acid (CT3, IP-751, Indevus Pharmaceuticals) ([Figure 1](#fig1){ref-type="fig"}).

In 1988, the first cannabinoid receptor was identified (CB~1~) ([@b71]) and in 1993, a second was described (CB~2~) ([@b99]). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB~1~ is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord ([@b66]; [@b67]), as well as the peripheral nervous system ([@b47]; [@b38]) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated ([@b38]). CB~2~, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes ([@b89]). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain ([@b36]), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue ([@b96]) ([Figure 1](#fig1){ref-type="fig"}). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands ("endocannabinoids") and metabolizing enzymes comprise the endocannabinoid system (ECS) ([@b37]), whose functions have been prosaically termed to be "relax, eat, sleep, forget and protect" (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (*Cannabis sativa*, *C. indica*) (THC, CBD and others), opium poppy (*Papaver somniferun*) (morphine, codeine), chile peppers (eg, *Capsicum annuum*, *C. frutescens*, *C. chinense*) (capsaicin) and willow bark (*Salix* spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB~1~ receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see [@b108], while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain ([@b151]).

A clinical endocannabinoid deficiency has been postulated to be operative in certain treatment-resistant conditions ([@b123]), and has received recent support in findings that anandamide levels are reduced over controls in migraineurs (Sarchielli et al 2006), that a subset of fibromyalgia patients reported significant decreased pain after THC treatment ([@b132]), and the active role of the ECS in intestinal pain and motility in irritable bowel syndrome ([@b94]) wherein anecdotal efficacy of cannabinoid treatments have also been claimed.

The endocannabinoid system is tonically active in control of pain, as demonstrated by the ability of SR141716A (rimonabant), a CB~1~ antagonist, to produce hyperalgesia upon administration to mice ([@b116]). As mentioned above, the ECS is active throughout the neuraxis, including integrative functions in the periacqueductal gray ([@b149]; [@b150]), and in the ventroposterolateral nucleus of the thalamus, in which cannabinoids proved to be 10-fold more potent than morphine in wide dynamic range neurons mediating pain ([@b93]). The ECS also mediates central stress-induced analgesia ([@b69]), and is active in nociceptive spinal areas ([@b68]; [@b117]) including mechanisms of wind-up ([@b140]) and N-methyl-D-aspartate (NMDA) receptors ([@b118]). It was recently demonstrated that cannabinoid agonists suppress the maintenance of vincristine-induced allodynia through activation of CB~1~ and CB~2~ receptors in the spinal cord ([@b113]). The ECS is also active peripherally ([@b119]) where CB~1~ stimulation reduces pain, inflammation and hyperalgesia. These mechanisms were also proven to include mediation of contact dermatitis via CB~1~ and CB~2~ with benefits of THC noted systemically and locally on inflammation and itch ([@b77]). Recent experiments in mice have even suggested the paramount importance of peripheral over central CB~1~ receptors in nociception of pain ([@b4])

Cannabinoid agonists produce many effects beyond those mediated directly on receptors, including anti-inflammatory effects and interactions with various other neurotransmitter systems (previously reviewed ([@b124]). Briefly stated, THC effects in serotonergic systems are widespread, including its ability to decrease 5-hydroxytryptamine (5-HT) release from platelets ([@b145]), increase its cerebral production and decrease synaptosomal uptake ([@b136]). THC may affect many mechanisms of the trigeminovascular system in migraine ([@b6]; [@b7]; [@b5]; [@b121]; [@b122]). Dopaminergic blocking actions of THC ([@b98]) may also contribute to analgesic benefits.

The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms ([@b104]). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release ([@b133]), THC produces 30%--40% reduction in NMDA responses, and THC is a neuroprotective antioxidant ([@b64]). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide ([@b117]). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia ([@b84]), and THC will do so at sub-psychoactive doses in experimental animals ([@b81]). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production ([@b92]), may allow opiate sparing in clinical application ([@b28]), prevents development of tolerance to and withdrawal from opiates ([@b29]), and rekindles opiate analgesia after a prior dosage has worn off ([@b29]). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.

The anti-inflammatory contributions of THC are also extensive, including inhibition of PGE-2 synthesis ([@b22]), decreased platelet aggregation ([@b131]), and stimulation of lipooxygenase ([@b43]). THC has twenty times the anti-inflammatory potency of aspirin and twice that of hydrocortisone ([@b42]), but in contrast to all nonsteroidal anti-inflammatory drugs (NSAIDs), demonstrates no cyclo-oxygenase (COX) inhibition at physiological concentrations ([@b138]).

Cannabidiol, a non-euphoriant phytocannabinoid common in certain strains, shares neuroprotective effects with THC, inhibits glutamate neurotoxicity, and displays antioxidant activity greater than ascorbic acid (vitamin C) or tocopherol (vitamin E) ([@b64]). While THC has no activity at vanilloid receptors, CBD, like AEA, is a TRPV~1~ agonist that inhibits fatty acid amidohydrolase (FAAH), AEA's hydrolytic enzyme, and also weakly inhibits AEA reuptake ([@b16]). These activities reinforce the conception of CBD as an endocannabinoid modulator, the first clinically available ([@b126]). CBD additionally affects THC function by inhibiting first pass hepatic metabolism to the possibly more psychoactive 11-hydroxy-THC, prolonging its half-life, and reducing associated intoxication, panic, anxiety and tachycardia ([@b126]). Additionally, CBD is able to inhibit tumor necrosis factor-alpha (TNF-α) in its own right in a rodent model of rheumatoid arthritis ([@b91]). At a time when great concern is accruing in relation to NSAIDs in relation to COX-1 inhibition (gastrointestinal ulcers and bleeding) and COX-2 inhibition (myocardial infarction and cerebrovascular accidents), CBD, like THC, inhibits neither enzyme at pharmacologically relevant doses ([@b138]). A new explanation of inflammatory and analgesic effects of CBD has recently come to light with the discovery that it is able to promote signaling of the adenosine receptor A2A by inhibiting the adenosine transporter ([@b26]).

Other "minor phytocannabinoids" in cannabis may also contribute relevant activity ([@b95]). Cannabichromene (CBC) is the third most prevalent cannabinoid in cannabis, and is also anti-inflammatory ([@b153]), and analgesic, if weaker than THC ([@b33]). Cannabigerol (CBG) displays sub-micromolar affinity for CB~1~ and CB~2~ ([@b51]). It also exhibits GABA uptake inhibition to a greater extent than THC or CBD ([@b9]), suggesting possible utilization as a muscle relaxant in spasticity. Furthermore, CBG has more potent analgesic, anti-erythema and lipooxygenase blocking activity than THC ([@b42]), mechanisms that merit further investigation. It requires emphasis that drug stains of North American ([@b40]; [@b97]), and European ([@b80]) cannabis display relatively high concentrations of THC, but are virtually lacking in CBD or other phytocannabinoid content.

Cannabis terpenoids also display numerous attributes that may be germane to pain treatment ([@b95]). Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone ([@b114]), suggesting an opioid-like mechanism. It also blocks inflammation via PGE-2 ([@b87]). The cannabis sesquiterpenoid β-caryophyllene shows increasing promise in this regard. It is anti-inflammatory comparable to phenylbutazone via PGE-1 ([@b12]), but simultaneously acts as a gastric cytoprotective ([@b142]). The analgesic attributes of β-caryophyllene are increasingly credible with the discovery that it is a selective CB~2~ agonist ([@b53]), with possibly broad clinical applications. α-Pinene also inhibits PGE-1 ([@b56]), while linalool displays local anesthetic effects ([@b115]).

Cannabis flavonoids in whole cannabis extracts may also contribute useful activity ([@b95]). Apigenin inhibits TNF-α ([@b52]), a mechanism germane to multiple sclerosis and rheumatoid arthritis. Cannflavin A, a flavone unique to cannabis, inhibits PGE-2 thirty times more potently than aspirin ([@b11]), but has not been subsequently investigated.

Finally, β-sitosterol, a phytosterol found in cannabis, reduced topical inflammation 65% and chronic edema 41% in skin models ([@b57]).

Available cannabinoid analgesic agents and those in development
===============================================================

Very few randomized controlled trials (RCTs) have been conducted using smoked cannabis ([@b25]) despite many anecdotal claims ([@b59]). One such study documented slight weight gain in HIV/AIDS subjects with no significant immunological sequelae ([@b2]). A recent brief trial of smoked cannabis (3.56% THC cigarettes 3 times daily) in HIV-associated neuropathy showed positive results on daily pain, hyperalgesia and 30% pain reduction (vs 15% in placebo) in 50 subjects over a treatment course of only 5 days ([@b3]) ([Table 1](#tbl1){ref-type="table"}). This short clinical trial also demonstrated prominent adverse events associated with intoxication. In Canada, 21 subjects with chronic pain sequentially smoked single inhalations of 25 mg of cannabis (0, 2.5, 6.0, 9.5% THC) via a pipe three times a day for 5 days to assess effects on pain ([@b152]) with results the authors termed "modest": no changes were observed in acute neuropathic pain scores, and a very low number of subjects noted 30% pain relief at the end of the study ([Table 1](#tbl1){ref-type="table"}). Even after political and legal considerations, it remains extremely unlikely that crude cannabis could ever be approved by the FDA as a prescription medicine as outlined in the FDA Botanical Guidance document ([@b46]; [@b125]), due to a lack of rigorous standardization of the drug, an absence of Phase III clinical trials, and pulmonary sequelae (bronchial irritation and cough) associated with smoking ([@b143]). Although cannabis vaporizers reduce potentially carcinogenic polyaromatic hydrocarbons, they have not been totally eliminated by this technology ([@b55]; [@b65]). Table 1Results RCTs of cannabinoids in treatment of pain syndromes ()DrugSubject number N =RCT indicationTrial durationResults/ReferenceAjulemic Acid21Neuropathic pain7 day crossoverVAS improved over placebo (p = 0.02) ([@b78])Cannabis, smoked50HIV neuropathy5 daysDecreased daily pain (p = 0.03) and hyperalgesia (p = 0.05), 52% with \>30% pain reduction vs placebo (p = 0.04) ([@b3])Cannabis, Smoked21Chronic neuropathic pain5 daysNo acute benefit on pain, average daily pain lower on high THC cannabis vs placebo (p = 0.02 ) ([@b152])Cannador419Pain due to spasm in MS15 weeksImprovement over placebo in subjective pain associated with spasm (p = 0.003) ([@b155])Cannador65Post-herpetic neuralgia4 weeksNo benefit observed ([@b41])Cannador30Post-operative painSingle doses, dailyDecreasing pain intensity with increased dose (p = 0.01)([@b70])Marinol24Neuropathic pain in MS15--21 days, crossoverMedian numerical pain (p = 0.02), median pain relief improved (p = 0.035) over placebo ([@b141])Marinol40Post-operative painSingle doseNo benefit observed over placebo ([@b21])Nabilone41Post-operative pain3 doses in 24 hoursNSD morphine consumption. Increased pain at rest and on movement with nabilone 1 or 2 mg ([@b13])Sativex20Neurogenic painSeries of 2-week N-of-1 crossover blocksImprovement with Tetranabinex and Sativex on VAS pain vs placebo (p \< 0.05), symptom control best with Sativex (p \< 0.0001) ([@b148])Sativex24Chronic intractable pain12 weeks, series of N-of-1 crossover blocksVAS pain improved over placebo (p \< 0.001) especially in MS (p \< 0.0042) ([@b106])Sativex48Brachial plexus avulsion6 weeks in 3 two-week crossover blocksBenefits noted in Box Scale-11 pain scores with Tetranabinex (p = 0.002) and Sativex (p = 0.005) over placebo ([@b15])Sativex66Central neuropathic pain in MS5 weeksNRS analgesia improved over placebo (p = 0.009) ([@b120])Sativex125Peripheral neuropathic pain5 weeksImprovements in NRS pain levels (p = 0.004), dynamic allodynia (p = 0.042), and punctuate allodynia (p = 0.021) vs placebo ([@b107])Sativex56Rheumatoid arthritisNocturnal dosing for 5 weeksImprovements over placebo morning pain on movement (p = 0.044), morning pain at rest (p = 0.018), DAS-28 (p = 0.002), and SF-MPQ pain at present (p = 0.016) ([@b17])Sativex117Pain after spinal injury10 daysNSD in NRS pain socres, but improved Brief Pain Inventory (p = 0.032), and Patients Global Impression of Change (p = 0.001) (unpublished)Sativex177Intractable cancer pain2 weeksImprovements in NRS analgesia vs placebo (p = 0.0142), Tetranabinex NSD ([@b74])Sativex135Intractable lower urinary tract symptoms in MS8 weeksImproved bladder severity symptoms including pain over placebo (p = 0.001) (unpublished)[^1]

Oral dronabinol (THC) is marketed in synthetic form as Marinol^®^ (Solvay Pharmaceuticals) in various countries, and was approved in the USA for nausea associated with chemotherapy in 1985, and in 1992 for appetite stimulation in HIV/AIDS. Oral dronabinol's expense, variability of action, and attendant intoxication and dysphoria have limited its adoption by clinicians ([@b24]). Two open label studies in France of oral dronabinol for chronic neuropathic pain in 7 subjects ([@b32]) and 8 subjects ([@b8]), respectively, failed to show significant benefit on pain or other parameters, and showed adverse event frequently requiring discontinuation with doses averaging 15--16.6 mg THC. Dronabinol did demonstrate positive results in a clinical trial of multiple sclerosis pain in two measures ([@b141]), but negative results in post-operative pain ([@b21]) ([Table 1](#tbl1){ref-type="table"}). Another uncontrolled case report in three subjects noted relief of intractable pruritus associated with cholestatic jaundice employing oral dronabinol ([@b102]). Some authors have noted patient preference for whole cannabis preparations over oral THC ([@b76]), and the contribution of other components beyond THC to therapeutic benefits ([@b95]). Inhaled THC leads to peak plasma concentration within 3--10 minutes, followed by a rapid fall while levels of intoxication are still rising, and with systemic bioavailability of 10%--35% ([@b61]). THC absorption orally is slow and erratic with peak serum levels in 45--120 minutes or longer. Systemic bioavailability is also quite low due to rapid hepatic metabolism on first pass to 11-hydroxy-THC. A rectal suppository of THC-hemisuccinate is under investigation ([@b19]), as are transdermal delivery techniques ([@b27]). The terminal half-life of THC is quite prolonged due to storage in body lipids ([@b61]).

Nabilone (Cesamet) ([Figure 1](#fig1){ref-type="fig"}), is a synthetic dimethylheptyl analogue of THC (British Medical Association 1997) that displays greater potency and prolonged half-life. Serum levels peak in 1--4 hours ([@b83]). It was also primarily developed as an anti-emetic in chemotherapy, and was recently re-approved for this indication in the USA. Prior case reports have noted analgesic effects in case reports in neuropathic pain ([@b105]) and other pain disorders ([@b14]). Sedation and dysphoria were prominent sequelae. An RCT of nabilone in 41 post-operative subjects actually documented exacerbation of pain scores after thrice daily dosing ([@b13]) ([Table 1](#tbl1){ref-type="table"}). An abstract of a study of 82 cancer patients on nabilone claimed improvement in pain levels after varying periods of follow-up compared to patients treated without this agent ([@b90]). However, 17 subjects dropped out, and the study was neither randomized nor controlled, and therefore is not included in [Table 1](#tbl1){ref-type="table"}.

Ajulemic acid (CT3, IP-751) ([Figure 1](#fig1){ref-type="fig"}), another synthetic dimethylheptyl analogue, was employed in a Phase II RCT in 21 subjects with improvement in peripheral neuropathic pain ([@b78]) ([Table 1](#tbl1){ref-type="table"}). Part of its analgesic activity may relate to binding to intracellular peroxisome proliferator-activator receptor gamma ([@b86]). Peak plasma concentrations have generally been attained in 1--2 hours, but with delays up to 4--5 hours is some subjects ([@b78]). Debate surrounds the degree of psychoactivity associated with the drug ([@b39]). Current research is confined to the indication of interstitial cystitis.

Cannador^®^ (IKF-Berlin) is a cannabis extract administered in oral capsules, with differing figures as to THC:CBD ratios (reviewed in ([@b126])), generally approximately 2:1. Two pharmacokinetic studies on possibly related material have been reported ([@b100]; [@b101]). In a Phase III RCT employing Cannador in spasticity in multiple sclerosis (MS) (CAMS) ([@b155]) ([Table 1](#tbl1){ref-type="table"}), no improvement was noted in the Ashworth Scale, but benefit was observed in spasm-associated pain on subjective measures. Both Marinol and Cannador produced reductions in pain scores in long-term follow-up ([@b156]). Cannador was assayed in postherpetic neuralgia in 65 subjects with no observed benefit ([@b41]) ([Table 1](#tbl1){ref-type="table"}), and in 30 post-operative pain subjects (CANPOP) without opiates, with slight benefits, but prominent psychoactive sequelae ([@b70]) ([Table 1](#tbl1){ref-type="table"}).

Sativex^®^ (GW Pharmaceuticals) is an oromucosal whole cannabis-based spray combining a CB~1~ partial agonist (THC) with a cannabinoid system modulator (CBD), minor cannabinoids and terpenoids plus ethanol and propylene glycol excipients and peppermint flavoring ([@b95]; [@b126]). It was approved by Health Canada in June 2005 for prescription for central neuropathic pain in multiple sclerosis, and in August 2007, it was additionally approved for treatment of cancer pain unresponsive to optimized opioid therapy. Sativex is a highly standardized pharmaceutical product derived from two *Cannabis sativa* chemovars following Good Agricultural Practice (GAP) ([@b34]), yielding Tetranabinex^®^ (predominantly-THC extract) and Nabidiolex^®^ (predominantly-CBD extract) in a 1:1 ratio. Each 100 μL pump-action oromucosal Sativex spray actuation provides 2.7 mg of THC and 2.5 mg of CBD. Pharmacokinetic data are available, and indicate plasma half lives of 85 minutes for THC, 130 minutes for 11-hydroxy-THC and 100 minutes for CBD ([@b63]). Sativex effects commence in 15--40 minutes, an interval that permits symptomatic dose titration. A very favorable adverse event profile has been observed in over 2500 patient years of exposure in over 2000 experimental subjects. Patients most often ascertain an individual stable dosage within 7--10 days that provides therapeutic relief without unwanted psychotropic effects (often in the range of 8--10 sprays per day). In all RCTs, Sativex was adjunctively added to optimal drug regimens in subjects with intractable symptoms, those often termed "untreatable." Sativex is also available by named patient prescription in the UK and the Catalonia region of Spain. An Investigational New Drug (IND) application to study Sativex in advanced clinical trials in the USA was approved by the FDA in January 2006 in patients with intractable cancer pain.

The clinical trials performed with Sativex have recently been assessed in two independent review articles ([@b10]; [@b110]). In a Phase II clinical trial in 20 patients with neurogenic symptoms ([@b148]), Tetranabinex, Nabidiolex, and Sativex were tested in a double-blind RCT vs placebo ([Table 1](#tbl1){ref-type="table"}). Significant improvement was seen with both Tetranabinex and Sativex on pain (especially neuropathic), but post-hoc analysis showed symptom control was best with Sativex (p \< 0.0001), with less intoxication than with THC-predominant extract.

In a Phase II double-blind crossover study of intractable chronic pain ([@b106]) in 24 subjects, visual analogue scales (VAS) were 5.9 for placebo, 5.45 for Nabidiolex, 4.63 for Tetranabinex and 4.4 for Sativex extracts (p \< 0.001). Sativex produced best results for pain in MS subjects (p \< 0.0042) ([Table 1](#tbl1){ref-type="table"}).

In a Phase III study of pain associated due to brachial plexus avulsion (N = 48) ([@b15]), fairly comparable benefits were noted in Box Scale-11 pain scores with Tetranabinex and Sativex extracts ([Table 1](#tbl1){ref-type="table"}).

In a controlled double-blind RCT of central neuropathic pain, 66 MS subjects showed mean Numerical Rating Scale (NRS) analgesia favoring Sativex over placebo ([@b120]) ([Table 1](#tbl1){ref-type="table"}).

In a Phase III double-blind, placebo-controlled trial (N = 125) of peripheral neuropathic pain with allodynia ([@b107]), Sativex produced highly statistically significant improvements in pain levels, dynamic and punctate allodynia ([Table 1](#tbl1){ref-type="table"}).

In a SAFEX study of Phase III double-blind RCT in 160 subjects with various symptoms of MS ([@b146]), 137 patients elected to continue on Sativex after the initial study ([@b147]). Rapid declines were noted in the first twelve weeks in pain VAS (N = 47) with slower sustained improvements for more than one year. During that time, there was no escalation of dose indicating an absence of tolerance to the preparation. Similarly, no withdrawal effects were noted in a subset of patients who voluntarily stopped the medicine abruptly. Upon resumption, benefits resumed at the prior established dosages.

In a Phase II double-blind, randomized, placebo-controlled, 5-week study of 56 rheumatoid arthritis patients with Sativex ([@b17]), employed nocturnal treatment only to a maximum of 6 sprays per evening (16.2 mg THC + 15 mg CBD). In the final treatment week, morning pain on movement, morning pain at rest, DAS-28 measure of disease activity, and SF-MPQ pain at present all favored Sativex over placebo ([Table 1](#tbl1){ref-type="table"}).

Results of a Phase III study (N = 177) comparing Sativex, THC-predominant extract and placebo in intractable pain due to cancer unresponsive to opiates ([@b74]) demonstrated that Sativex produced highly statistically significant improvements in analgesia ([Table 1](#tbl1){ref-type="table"}), while the THC-predominant extract failed to produce statistical demarcation from placebo, suggesting the presence of CBD in the Sativex preparation was crucial to attain significant pain relief.

In a study of spinal injury pain, NRS of pain were not statistically different from placebo, probably due to the short duration of the trial, but secondary endpoints were clearly positive ([Table 1](#tbl1){ref-type="table"}). Finally, in an RCT of intractable lower urinary tract symptoms in MS, accompanying pain in affected patients was prominently alleviated ([Table 1](#tbl1){ref-type="table"}).

Highly statistically significant improvements have been observed in sleep parameters in virtually all RCTs performed with Sativex in chronic pain conditions leading to reduced "symptomatic insomnia" due to symptom reduction rather than sedative effects (Russo et al 2007).

Common adverse events (AE) of Sativex acutely in RCTs have included complaints of bad taste, oral stinging, dry mouth, dizziness, nausea or fatigue, but do not generally necessitate discontinuation, and prove less common over time. While there have been no head-to-head comparative RCTs of Sativex with other cannabinoid agents, certain contrasts can be drawn. Sativex ([@b120]) and Marinol ([@b141]) have both been examined in treatment of central neuropathic pain in MS, with comparable results ([Table 1](#tbl1){ref-type="table"}). However, adverse events were comparable or greater with Marinol than with Sativex employing THC dosages some 2.5 times higher due to the presence of accompanying CBD ([@b125]; [@b126]).

Similarly, while Sativex and smoked cannabis have not been employed in the same clinical trial, comparisons of side effect profiles can be made on the basis of SAFEX studies of Sativex for over a year and up to several years in MS and other types of neuropathic pain ([@b125]; [@b147]), and government-approved research programs employing standardized herbal cannabis from Canada for chronic pain ([@b88]) and the Netherlands for general conditions ([@b73]; [@b58]) over a period of several months or more. As is evident in Figure 2 ([Figure 2](#fig2){ref-type="fig"}), all adverse events are more frequently reported with herbal cannabis, except for nausea and dizziness, both early and usually transiently reported with Sativex (see ([@b125]) for additional discussion).

![Comparison of adverse events (AE) encountered with long term therapeutic use of herbal cannabis in the Netherlands ([@b73]; [@b58]) and Canada ([@b88]), vs that observed in safety-extension (SAFEX) studies of Sativex oromucosal spray ([@b126]; [@b147]).](tcrm0401-245-02){#fig2}

Practical issues with cannabinoid medicines
===========================================

Phytocannabinoids are lipid soluble with slow and erratic oral absorption. While cannabis users claim that the smoking of cannabis allows easy dose titration as a function of rapid onset, high serum levels in a short interval inevitably result. This quick onset is desirable for recreational purposes, wherein intoxication is the ultimate goal, but aside from paroxysmal disorders (eg, episodic trigeminal neuralgia or cluster headache attack), such rapid onset of activity is not usually necessary for therapeutic purposes in chronic pain states. As more thoroughly reviewed elsewhere ([@b125]), cannabis smoking produces peak levels of serum THC above 140 ng/mL ([@b60]; [@b72]), while comparable amounts of THC in Sativex administered oromucosally remained below 2 ng/mL ([@b63]).

The vast majority of subjects in Sativex clinical trials do not experience psychotropic effects outside of initial dose titration intervals ([Figure 2](#fig2){ref-type="fig"}) and most often report subjective intoxication levels on visual analogue scales that are indistinguishable from placebo, in the single digits out of 100 ([@b147]). Thus, it is now longer tenable to claim that psychoactive effects are a necessary prerequisite to symptom relief in the therapeutic setting with a standardized intermediate onset cannabis-based preparation. Intoxication has remained a persistent issue in Marinol usage ([@b24]), in contrast.

Recent controversies have arisen in relation to non-steroidal anti-inflammatory drugs (NSAID), with concerns that COX-1 agents may provoke gastrointestinal ulceration and bleeding, and COX-2 drugs may increase incidents of myocardial infarction and cerebrovascular accidents ([@b45]; [@b144]). In contrast, neither THC nor CBD produce significant COX inhibition at normal dosage levels ([@b138]).

Frequent questions have been raised as to whether psychoactive drugs may be adequately blinded (masked) in randomized clinical trials. Internal review and outside analysis have confirmed that blinding in Sativex spasticity studies has been effective ([@b31]; [@b154]). Sativex and its placebo are prepared to appear identical in taste and color. About half of clinical trial subjects reported previous cannabis exposure, but results of two studies ([@b120]; [@b107]) support the fact that cannabis-experienced and naïve patients were identical in observed efficacy and adverse event reporting

Great public concern attends recreational cannabis usage and risks of dependency. The addictive potential of a drug is assessed on the basis of five elements: intoxication, reinforcement, tolerance, withdrawal and dependency. Drug abuse liability (DAL) is also assessed by examining a drug\'s rates of abuse and diversion. US Congress placed cannabis in Schedule I of the Controlled Substances Act in 1970, with drugs categorized as addictive, dangerous, possessing severe abuse potential and no recognized medical value. Marinol was placed in Schedule II, the category for drugs with high abuse potential and liability to produce dependency, but certain recognized medical uses, after its FDA approval in 1985. Marinol was reassigned to Schedule III in 1999, a category denoting a lesser potential for abuse or lower dependency risk after documentation that little abuse or diversion ([@b24]) had occurred. Nabilone was placed and has remained in Schedule II since 1985.

The degree to which a drug is reinforcing is determined partly by the by the rate of its delivery to the brain ([@b129]). Sativex has effect onset in 15--40 minutes, peaking in a few hours, quite a bit slower than drugs of high abuse potential. It has been claimed that inclusion of CBD diminishes psychoactive effects of THC, and may lower potential drug abuse liability of the preparation (see [@b125])) for discussion). Prior studies from Sativex clinical trials do not support the presence reinforcement or euphoria as problems in administration ([@b147]).

Certain facets of acute cannabinoid exposure, including tachycardia, hypothermia, orthostatic hypotension, dry mouth, ocular injection, intraocular pressure decreases, etc. are subject to rapid tachyphylaxis upon continued administration ([@b75]). No dose tolerance to the therapeutic effects of Sativex has been observed in clinical trials in over 1500 patient-years of administration. Additionally, therapeutic efficacy has been sustained for several years in a wide variety of symptoms; SAFEX studies in MS and peripheral neuropathic pain, confirm that Sativex doses remain stable or even decreased after prolonged usage ([@b147]), with maintenance of therapeutic benefit and even continued improvement.

Debate continues as to the existence of a clinically significant cannabis withdrawal syndrome with proponents ([@b20]), and questioners ([@b134]). While withdrawal effects have been reported in recreational cannabis smokers ([@b135]), 24 volunteers with MS who abruptly stopped Sativex after more than a year of continuous usage displayed no withdrawal symptoms meeting Budney's criteria. While symptoms recurred after 7--10 days of abstinence from Sativex, prior levels of symptom control were readily re-established upon re-titration of the agent ([@b147]).

Overall, Sativex appears to pose less risk of dependency than smoked cannabis based on its slower onset, lower dosage utilized in therapy, almost total absence of intoxication in regular usage, and minimal withdrawal symptomatology even after chronic administration. No known abuse or diversion incidents have been reported with Sativex to date (as of November 2007). Sativex is expected to be placed in Schedule IV of the Misuse of Drugs Act in the United Kingdom once approved.

Cognitive effects of cannabis have been reviewed ([@b128]; [@b48]), but less study has occurred in therapeutic contexts. Effects of chronic heavy recreational cannabis usage on memory abate without sequelae after a few weeks of abstinence ([@b112]). Studies of components of the Halstead-Reitan battery with Sativex in neuropathic pain with allodynia have revealed no changes vs placebo ([@b107]), and in central neuropathic pain in MS ([@b120]), 4 of 5 tests showed no significant differences. While the Selective Reminding Test did not change significantly on Sativex, placebo patients displayed unexpected improvement.

Slight improvements were observed in Hospital Anxiety and Depression Scales depression and anxiety scores were noted with Sativex in MS patients with central neuropathic pain ([@b120]), although not quite statistically significant. No long-term mood disorders have been associated with Sativex administration.

Debate continues with regard to the relationship between cannabis usage and schizophrenia (reviewed ([@b48])). An etiological relationship is not supported by epidemiological data ([@b35]), but if present, should bear relation to dose and length of high exposure. It is likely that lower serum levels of Sativex in therapeutic usage, in conjunction with anti-psychotic properties of CBD ([@b157]), would minimize risks. Children and adolescents have been excluded from Sativex RCTs to date. SAFEX studies of Sativex have yielded few incidents of thought disorder, paranoia or related complaints.

Adverse effects of cannabinoids on immune function have been observed in experimental animals at doses 50--100 times the psychoactive level ([@b23]). In four patients using herbal cannabis therapeutically for over 20 years, no abnormalities were observed in leukocyte, CD4 or CD8 cell counts ([@b128]). Investigation of MS patients on Cannador revealed no major immune changes ([@b79]), and similarly, none occurred with smoked cannabis in a short-term study of HIV patients ([@b2]). Hematological measures have been normal in all Sativex RCTs without clinical signs of immune dysfunction.

Concerns are frequently noted with new drug-drug interactions, but few have resulted in Sativex RCTs despite its adjunctive use with opiates, many other psychoactive analgesic, antidepressant and anticonvulsant drugs ([@b124]), possibly due to CBD ability to counteract sedative effects of THC ([@b103]). No effects of THC extract, CBD extract or Sativex were observed in a study of effects on the hepatic cytochrome P450 complex ([@b139]). On additional study, at 314 ng/ml cannabinoid concentration, Sativex and components produced no significant induction on human CYP450 ([@b137]). Thus, Sativex should be safe to use in conjunction with other drugs metabolized via this pathway.

The Marinol patient monograph cautions that patients should not drive, operate machinery or engage in hazardous activities until accustomed to the drug's effects (<http://www.solvaypharmaceuticals-us.com/static/wma/pdf/1/3/1/9/Marinol5000124ERev52003.pdf>). The Sativex product monograph in Canada (<http://www.bayerhealth.ca/display.cfm?Object_ID=272&Article_ID=121&expandMenu_ID=53&prevSubItem=5_52>) suggests that patients taking it should not drive automobiles. Given that THC is the most active component affecting such abilities, and the low serum levels produced in Sativex therapy (vide supra), it would be logical that that patients may be able to safely engage in such activities after early dose titration and according to individual circumstances, much as suggested for oral dronabinol. This is particularly the case in view of a report by an expert panel ([@b62]) that comprehensively analyzed cannabinoids and driving. It suggested scientific standards such as roadside sobriety tests, and THC serum levels of 7--10 ng/mL or less, as reasonable approaches to determine relative impairment. No studies have demonstrated significant problems in relation to cannabis affecting driving skills at plasma levels below 5 ng/mL of THC. Prior studies document that 4 rapid oromucosal sprays of Sativex (greater than the average single dose employed in therapy) produced serum levels well below this threshold ([@b125]). Sativex is now well established as a cannabinoid agent with minimal psychotropic effect.

Cannabinoids may offer significant "side benefits" beyond analgesia. These include anti-emetic effects, well established with THC, but additionally demonstrated for CBD ([@b111]), the ability of THC and CBD to produce apoptosis in malignant cells and inhibit cancer-induced angiogenesis ([@b82]; [@b85]), as well as the neuroprotective antioxidant properties of the two substances ([@b64]), and improvements in symptomatic insomnia (Russo et al 2007).

The degree to which cannabinoid analgesics will be adopted into adjunctive pain management practices currently remains to be determined. Data on Sativex use in Canada for the last reported 6-month period (January-July 2007) indicated that 81% of prescriptions issued for patients in that interval were refills (data on file, from Brogan Inc Rx Dynamics), thus indicating in some degree an acceptance of, and a desire to, continue such treatment. Given their multi-modality effects upon various nociceptive pathways, their adjunctive side benefits, the efficacy and safety profiles to date of specific preparations in advanced clinical trials, and the complementary mechanisms and advantages of their combination with opioid therapy, the future for cannabinoid therapeutics appears very bright, indeed.

[^1]: **Abbreviations:** MS, multiple sclerosis; NRS, numerical rating scale; NSD, no signifi cant difference; RCTs, randomized clinical trials; VAS, visual analogue pain scales.
